Daniel P. Smith

University of Calgary — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

35h-index11.6kcitations148works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gut microbiota and health(45), Microbial Community Ecology and Physiology(13), Cancer Research and Treatments(12), Genomics and Phylogenetic Studies(11), Infant Nutrition and Health(7)

Publications142 total

Canadian Spine SocietyAbstract ID 19. Program Code CPSS01. Pediatric Spine Frailty Index predicts morbidity and mortality in spinal deformity surgeryAbstract ID 99. Program Code CPSS02. Evaluation of biplane radiographic systems for scoliotic patientsAbstract ID 180. Program Code CPSS03. Rate of spinal osteochondromas diagnosed via advanced imaging in pediatric patients with hereditary multiple osteochondromas: a systematic review and meta-analysisAbstract ID 137. Program Code CPSS04. The impact of adverse childhood experiences on fibromyalgia: a systematic review and meta-analysis of case–control studiesAbstract ID 61. Program Code CPSS05. Enhanced recovery pathway for patients with adolescent idiopathic scoliosis undergoing posterior spinal instrumentation and fusion surgery: a matched controlled analysisAbstract ID 193. Program Code CPSS06. Integrated approach to back pain in the adolescent populationAbstract ID 38. Program Code CPSS07. Traumatic spinal cord injury in children and adolescents: a 20-year review from the Hospital for Sick ChildrenAbstract ID 93. Program Code CPSS08. Prevalence and prognosis of scapular pain following surgical treatment of adolescent idiopathic scoliosis: a prospective study to guide preoperative counsellingAbstract ID 150. Program Code CPSS09. Preoperative zoledronate is safe for children with medical complexity undergoing posterior spinal fusion for neuromuscular scoliosisAbstract ID 15. Program Code CPSS10. Allogeneic transfusion is associated with adverse events in idiopathic scoliosis surgeryAbstract ID 56. Program Code A11. Defining the gaps in transitional care to adulthood for patients in pediatric surgical specialties: a scoping reviewAbstract ID 81. Program Code A12. Effect of mixing dissimilar metals on serum metal ion levels following spinal deformity surgeryAbstract ID 184. Program Code A13. Intraoperative neuromonitoring has poor correlation with postoperative neurological deficits in non-cord level adult deformity surgeryAbstract ID 94. Program Code A14. Role of somatosensory evoked potential (SSEP) in enhancing intraoperative neuromonitoring for spinal deformity surgery — results from a prospective multicentre studyAbstract ID 9. Program Code A15. Does fat matter? The association between extension of fusion and paraspinal muscle fat infiltrationAbstract ID 47. Program Code A16. Pelvic incidence to lumbar lordosis association varies by Roussouly morphotypeAbstract ID 102. Program Code A17. Association between rod and fusion mass fractures in adult spinal deformity: a retrospective cohort studyAbstract ID 8. Program Code A18. Design and implementation of a novel morselized bone interbody cage in posterior lumbar spinal fusion: a biomechanical studyAbstract ID 86. Program Code A19. Decompression versus decompression plus fusion for stable degenerative lumbar spondylolisthesis: comparing outcomes using propensity score–matched dataAbstract ID 176. Program Code A20. Reoperation rates for decompression and fusion versus decompression alone for degenerative spondylolisthesis: a comparative analysisAbstract ID 186. Program Code B21. Modic change is not associated with occult discitis or poor clinical outcome among patients treated surgically for lumbar disc herniation: prospective cohort studyAbstract ID 145. Program Code B22. Machine learning–driven clinical and imaging clustering of degenerative lumbar spondylolisthesis: implications for stratified surgical careAbstract ID 68. Program Code B23. Which psychosocial measures are most strongly related to surgical outcomes in patients with degenerative pathology of the spine?Abstract ID 111. Program Code B24. Acceptance and commitment therapy for patients with degenerative spinal disorders and maladaptive psychological processes: an observational studyAbstract ID 128. Program Code B25. Assessing construct validity of the Spine Adverse Events Severity System: impact of adverse event severity grade on longitudinal patient-reported outcomes)Abstract ID 72. Program Code B26. A pilot randomized controlled trial comparing traditional midline versus paramedian approaches to the lumbar spine for elective posterior/transforaminal lumbar interbody fusion proceduresAbstract ID 96. Program Code B27. Uniportal versus biportal endoscopic decompression for the treatment of lumbar spinal stenosis: a systematic review and updated meta-analysisAbstract ID 152. Program Code B28. Why business tools are essential for managing a spine programAbstract ID 172. Program Code B29. Relationship between fatty infiltration, frailty, and outcomes after spinal surgeryAbstract ID 143. Program Code C30. Clinical trajectory and outcomes with surgical intervention for traumatic central cord syndrome: impact of mechanism of injuryAbstract ID 13. Program Code C31. Optimal tracheostomy timing following traumatic complete spinal cord injury: a comparative analysis of ultra-early, early and delayed practiceAbstract ID 123. Program Code C32. Early stabilizatio
Canadian Journal of Surgery·2025Open Access
Table 2 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
2025Open Access
Figure 3 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
2025Open Access
Figure 5 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
2025Open Access
Table 1 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
2025Open Access
Figure 1 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
2025Open Access
Figure 2 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
2025Open Access
Figure 4 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
2025Open Access
Supplementary Figures S1-S3 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
2025Open Access
Electronic Origin of the Oxidizing Properties of Birnessite Minerals
Preprints.org·2025Open Access
hdf5lib: Headers and Static Libraries for 'HDF5'
2025
ecodive: Parallel and Memory-Efficient Ecological Diversity Metrics
2025Open Access
interprocess: Mutexes, Semaphores, and Message Queues
2025Open Access
webqueue: Multicore HTTP Server
2025Open Access
Artificial intelligence-augmented drug discovery identifies gefitinib as a potential treatment for ALS
2025Open Access
jobqueue: Run Interruptible Code Asynchronously
2025Open Access
Longitudinal phage–bacteria dynamics in the early life gut microbiome
Nature Microbiology·2025· 21 citedOpen Access
Succession Reimagined: Navigating the Winds of Change
2025
semaphore: Shared Memory Atomic Operations
2024Open Access
fillpattern: Patterned Fills for 'ggplot2' and 'grid' Graphics
2024Open Access
page 1 of 8Next →

Frequent Co-authors

Joseph F. Petrosino(19), Nadim J. Ajami(12), Jack A. Gilbert(9), Christopher J. Stewart(8), Stephen J. Giovannoni(8), John C. Alverdy(6), Matthew C. Wong(4), Benjamin D. Shogan(4), Nicholas D. Embleton(4), Janet Berrington(4), Kristi L. Hoffman(4), Thomas A. Auchtung(3), Simon Lax(3), Rob Knight(3), Perry L. McCarty(3), Baddr A. Shakhsheer(3), Stephen G. Weber(3), Emily Landon(3), Jeffrey A. Siegel(3), Olga Zaborina(3)